Tenacibaculum sp. Fermentation for Uric Acid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reducing uric acid levels in humans are inefficient due to contamination issues and long fermentation durations, with existing uricase-producing microorganisms requiring extensive culturing processes.
Innovation Solution
The use of Tenacibaculum sp. marine bacteria fermentation products, which are effective in reducing uric acid levels and can be produced within a shorter duration with reduced contamination risks, offering a novel approach for hyperuricemia treatment and uricase production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional uricase-producing microorganisms (Aspergillus sp., Bacillus sp.) are used, then uricase can be produced, but the fermentation duration is long and contamination easily occurs
Solution Approach 1:
The patent changes the microbial parameter from traditional Aspergillus/Bacillus species to Tenacibaculum sp. (a marine bacterium), which inherently provides resistance to contamination while reducing fermentation time. This parameter change in microbial selection resolves both the contamination and time issues simultaneously.
2Productivity
If traditional uricase-producing microorganisms are used, then uricase production is achieved, but the process requires extensive culturing and is inefficient
Solution Approach 1:
The patent changes the microbial parameter to Tenacibaculum sp., which demonstrates higher productivity in uricase production. The marine bacterium's metabolic characteristics enable faster growth and uricase synthesis, reducing the 5-day culturing period to a shorter duration while maintaining or enhancing production efficiency.
3Reliability
If xanthine oxidase inhibitors or uricase treatment is used for hyperuricemia, then uric acid levels are reduced, but treatment is not covered by health insurance and requires clinical intervention
Solution Approach 1:
The patent develops a health food product containing Tenacibaculum sp. fermentation products that can prevent or alleviate hyperuricemia symptoms without requiring clinical treatment. This self-service approach allows consumers to manage their own uric acid levels through dietary supplementation, making treatment accessible and insurance-free.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Tenacibaculum sp. fermentation products effectively lower blood uric acid levels, prevent and treat hyperuricemia-related diseases, and increase uric acid digestion, providing a potential alternative to existing uricase-producing organisms with improved efficiency and reduced contamination.
Implementation Method 1
Non-human mammals, such as rats and dogs, can produce uricase, which converts uric acid into micromolecular allantoin for excretion
Implementation Method 2
The use of Tenacibaculum sp. marine bacteria fermentation products, which are effective in reducing uric acid levels
Data Source
AI summary
The present invention relates to a method of reducing the level of uric acid in a subject, which comprises administering to said subject an effective amount of a fermentation product of Tenacibaculum sp. Also provided are a method of preventing and/or treating a disease or disorder related to hyperuricemia, a method of increasing the digestion of uric acid and a method of producing uricase.